

Announcement Summary

Entity name

AMPLIA THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

23/7/2025

The Proposed issue is: A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
ATX	ORDINARY FULLY PAID	10,869,566
Proposed +issue date		

29/8/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

AMPLIA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

16165160841

1.3 ASX issuer code

ATX

1.4 The announcement is New announcement

1.5 Date of this announcement

23/7/2025

1.6 The Proposed issue is: A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

 7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

 Yes

 7A.1a Conditions

 Approval/Condition
 Date for determination +Security holder approval

 27/8/2025

 Actual

Comments

Conditional Placement subject to shareholder approval for the purposes of ASX Listing Rule 7.1, to be considered at the Company's Annual General Meeting to be held on Wednesday 27 August 2025.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class Will the proposed issue of this +security include an offer of attaching +securities? No

Details of +securities proposed to be issued

ASX +security code and description

ATX : ORDINARY FULLY PAID

Number of +securities proposed to be issued

10,869,566


Offer price details

Are the +securities proposed to be issued being issued for a cash consideration? Yes

In what currency is the cash	What is the issue price per
consideration being paid?	+security?
AUD - Australian Dollar	AUD 0.23000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?





Yes

Part 7C - Timetable

7C.1 Proposed +issue date 29/8/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

27/8/2025

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

No

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

5.5%

No

7E.2 Is the proposed issue to be underwritten?

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Nil - costs reflected in those reported in Appendix 3B in respect of Placement and SPP announced earlier on 23 July 2025

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The Company is undertaking a capital raise which is expected to raise \$27.5 million to support the Company's ACCENT and AMPLICITY trials and initiate kRAS and OVARIAN trials of the Company's lead drug, Narmafotinib (AMP 945).

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

The Conditional Placement referred to herein is being undertaken in conjunction with a Placement, Share Purchase Plan and Director Placement to raise gross proceeds of \$27.5 million. The Conditional Placement, Director Placement and Share Purchase Plan are conditional on shareholder approval and will be considered at the Company's Annual General Meeting to be held on 27 August 2025.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)